IMTX
Immatics NV
NASDAQ · Healthcare · Biotechnology · DE
$7.05
+4.75%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$6.85
From 52W high−40.61%
Volume967050.00
Market cap$1.05B
P/E (TTM)—
P/S (TTM)22.5x
Div yield—
Key dataOct 19, 2026
Open
$6.85
From 52W high
−40.61%
Volume
967050.00
Market cap
$1.05B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.9x
P/E (TTM)
—
RSI (14)
37.2
MomentumView details →
1D Return
+4.75%
YTD Return
−32.19%
SummaryUpdated Jun 1, 2026
Immatics N.V. (NASDAQ:IMTX) is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in Tübingen, Germany. The company went public in December 2018 and focuses on developing innovative T cell receptor (TCR) based immunotherapies for cancer treatment. Immatics operates at the cutting edge of precision oncology, leveraging its proprietary technology platforms to identify cancer-specific targets and develop personalized immunotherapies. The company has established strategic partnerships with major pharmaceutical companies including GlaxoSmithKline, Genmab, and previously with Celgene, positioning itself as a leader in the emerging field of TCR-based cancer immunotherapy.
Similar companies
Latest newsMore news →